

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Codes

ICD-10 Codes:

XW033C3- Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3

XW043C3- Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3

ICD-10 Diagnosis Codes:

C91.00- Acute lymphoblastic leukemia not having achieved remission

C91.02- Acute lymphoblastic leukemia, in relapse

C82.0-C82.99- Follicular lymphoma

C83.30-C83.39- Diffuse large B-cell lymphoma

C85.20-C85.29- Mediastinal (thymic) large B-cell lymphoma

Z51.11- Encounter for antineoplastic chemotherapy

Z51.12- Encounter for antineoplastic immunotherapy

Drug Codes:

Q2042- Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Kymriah) – new code effective 1-1-19

Q2041- Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Yescarta)

Hospital Billing:

REV 87x = 087x Cell/Gene Therapy- Charges for procedures performed by staff for the acquisition and infusion/injection of genetically modified cells.

REV 89x = 089x Pharmacy - Extension of 025x and 063x- 0891 Special Processed Drugs - FDA Approved Cell Therapy(a) DRUGS/CELL THERAPY

Procedure Codes: for claims submitted on or after April 1, 2019

HCPCS 0537T with revenue code 0871- Collection/handling

HCPCS 0538T with revenue code 0872- Preparation for transport

HCPCS 0539T with revenue code 0873- Receipt and preparation